Posted by Michael Wonder on 21 Feb 2019
Canada finds "insufficient evidence" that Janssen blocked biosimilar competition
21 February 2019 - Despite the fact that the investigation confirmed many of the allegations against Janssen, the bureau concluded that, "at this time, there is insufficient evidence" that Janssen's conduct prevented competition.
Yesterday, Canada’s Competition Bureau, an independent law enforcement agency, announced that it is closing its investigation into whether Janssen, a division of Johnson & Johnson (J&J), engaged in conduct that hindered biosimilar competition.
The bureau was investigating allegations of predatory pricing and other anticompetitive practices related to Janssen’s originator infliximab, Remicade, that was allegedly intended to block competition from 2 approved biosimilar infliximab products: Samsung Bioepis and Merck’s Renflexis and Pfizer’s Inflectra.
